Related Experiment Video
Updated: May 31, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
CD38 and chronic lymphocytic leukemia: a decade later.
Fabio Malavasi1, Silvia Deaglio, Rajendra Damle
1Department of Genetics, Biology and Biochemistry, University of Torino School of Medicine, Torino, Italy. fabio.malavasi@unito.it
Blood
|July 19, 2011
Summary
CD38 is a key marker in chronic lymphocytic leukemia (CLL), indicating poor prognosis and driving cancer cell growth and migration. Further research will explore CD38 as a therapeutic target for this incurable leukemia.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- CD38 is a significant surface molecule in chronic lymphocytic leukemia (CLL).
- It serves as a reliable marker for unfavorable prognosis and indicates cellular activation and proliferation.
- Higher CD38 expression correlates with increased responsiveness to B-cell receptor (BCR) signaling and enhanced cell migration.
Purpose of the Study:
- To review a decade of research on the role of CD38 in CLL.
- To elucidate the mechanisms by which CD38 influences CLL cell behavior.
- To assess the potential of CD38 as a therapeutic target in CLL.
Main Methods:
- Review of scientific literature on CD38 and CLL.
- Analysis of signaling pathways involving CD38, ZAP-70, and ERK1/2.
- Investigation of CD38's role in proliferation, chemotaxis, and cell survival.
Main Results:
- CD38 activation in vitro promotes CLL proliferation and chemotaxis.
- CD38 acts as a molecular bridge, linking the cell to its environment and promoting survival over apoptosis.
- The microenvironment, involving molecules like CD38, supports leukemic cell growth and genetic alterations in CLL.
Conclusions:
- CD38 is a crucial factor in CLL pathogenesis, influencing cell survival, proliferation, and migration.
- The microenvironment plays a vital role in CLL progression, with CD38 being a key mediator.
- Future studies will determine if CD38 is a viable target for antibody-based therapies against CLL.
